NOAC (rivaroxaban) vs vitamin K antagonist (VKA)
Mean quality of life ‐ health utility · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 111 participantsLow